Inhaled insulin price?

Short answer:
- Inhaled insulin currently marketed in the U.S. is Afrezza (MannKind). Exubera was withdrawn from the market in 2007 and is no longer available.
- Price varies a lot by country, pharmacy, and insurance. In the U.S., the list price for Afrezza has been around the roughly $1,000–$1,100 per month before insurance, but your out-of-pocket can be much lower or higher depending on your plan, coupons, and patient-assistance programs.

What I can do:
- If you tell me your country, the pharmacy you use, and your typical monthly dose (or how many cartridges you’d expect to use), I can give a more tailored estimate.
- I can also point you to potential savings (manufacturer programs, GoodRx, etc.) or discuss alternatives if cost is a concern.

Notes:
- Afrezza dosing uses inhaled cartridges labeled with 4-, 8-, or 12-unit doses; pricing can vary by how many cartridges you need each day.
- Inhaled insulin requires lung function testing and isn’t suitable for everyone (smokers, certain lung conditions, etc.). Always discuss with your clinician.